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Background: Autism spectrum disorder (ASD) is highly heritable, but the genetic risk factors for it remain largely
unknown. Although structural variants with large effect sizes may explain up to 15% ASD, genome-wide association
studies have failed to uncover common single nucleotide variants with large effects on phenotype. The focus
within ASD genetics is now shifting to the examination of rare sequence variants of modest effect, which is most
often achieved via exome selection and sequencing. This strategy has indeed identified some rare candidate
variants; however, the approach does not capture the full spectrum of genetic variation that might contribute to
the phenotype.
Methods: We surveyed two loci with known rare variants that contribute to ASD, the X-linked neuroligin genes by
performing massively parallel Illumina sequencing of the coding and noncoding regions from these genes in males
from families with multiplex autism. We annotated all variant sites and functionally tested a subset to identify other
rare mutations contributing to ASD susceptibility.
Results: We found seven rare variants at evolutionary conserved sites in our study population. Functional analyses
of the three 3’ UTR variants did not show statistically significant effects on the expression of NLGN3 and NLGN4X. In
addition, we identified two NLGN3 intronic variants located within conserved transcription factor binding sites that
could potentially affect gene regulation.
Conclusions: These data demonstrate the power of massively parallel, targeted sequencing studies of affected
individuals for identifying rare, potentially disease-contributing variation. However, they also point out the
challenges and limitations of current methods of direct functional testing of rare variants and the difficulties of
identifying alleles with modest effects.
Keywords: Autism spectrum disorder, Massively parallel DNA sequencing, Rare variation, Evolutionary conservationBackground
The rapid development of better methods of targeted
enrichment and genome sequencing has made it possible
to detect a more complete spectrum of genetic variation
[1-3]. These approaches hold out the hope of uncovering
the genetic basis of polygenic complex human diseases,
including autism (OMIM 209850), a childhood-onset* Correspondence: mzwick@emory.edu
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reproduction in any medium, provided the ordisorder characterized by impaired social interactions,
abnormal verbal communication, restricted interests,
and repetitive behaviors. Autism has an estimated preva-
lence of one percent [4,5], and one of its most striking
epidemiological features is a four-fold excess of affected
male individuals.
Autism, or the broader autism spectrum disorder (ASD)
phenotype, is an example of a highly heterogenous, multi-
factorial disorder with substantial heritability [6-13], (see
reviews in [14,15]). Recent reports, in which X-chromosome
coding exons in individuals with ASD were sequenced, iden-
tified an excess of rare mutations predicted to be damagingral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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To date, more than 100 different genes and genomic
regions have been linked to this complex trait (see reviews
in [18,19]). Despite these findings, however, most of the
genetic risk for ASD remains unexplained. Recent studies
of ASD genetics generally adopt one of three study designs.
The first employs genome-wide association studies, which
have identified a few loci of interest, but largely failed
to replicate findings between studies [7,20,21]; a meta-
analysis of these studies, with a total of over 2500 study
subjects, reveals it is extremely unlikely that there is any
common variant influencing autism susceptibility, with an
odds ratio of greater than 1.5 [22]. The second design
focuses on large but very rare (frequency usually less than
one in a thousand in the general population) de novo
and inherited copy number variants (CNVs). Numerous
studies have now shown convincingly that this class of
rare variation makes a significant contribution to autism
susceptibility [23-34], explaining up to 15% of all ASD
cases. Unfortunately, these studies also point to a highly
heterogenous allelic architecture, as no single risk variant
is found in more than 1% of surveyed cases. The third has
applied exome sequencing to identify de novo or inherited
variants that contribute to ASD [35-37]. Overall, although
genetic studies have uncovered many candidate loci, much
ASD heritability remains unexplained [15].
Neuroligin pathway genes, including the neuroligins,
neurexins, and SHANK genes, are critical to synapse
development and function [38-40]. Several rare muta-
tions in neuroligin genes, including single nucleotide
variants (SNVs), insertions, splice variants, and deletions
of whole exons, have been implicated in the pathogenesis
of ASD [41-49]. These mutations often segregate with
ASD in families [41,42]; however, they are also associated
with variable cognitive phenotypes, including intellectual
disability (ID) [42,50], Tourette syndrome [46], and lan-
guage disability [43]. Neuroligin’s binding partners, the
neurexins, are also critical to synaptic function, and point
mutations and copy number variants in neurexin genes
have been linked to ASD [27,51-54]. In addition, variants
in the SHANK genes that anchor the neuroligins in the
post-synaptic density, are also implicated in ASD [29,55-
58]. There is therefore substantial evidence that perturba-
tions of genes from the neuroligin pathway contribute to
ASD susceptibility.
Most prior studies of neuroligin pathway genes have fo-
cused primarily on either discovering variants located
within exons or large CNVs that disrupt the locus (but see
[59]). Here we sought to test the hypothesis that rare
variants found at evolutionarily conserved sites within
noncoding regions might act as ASD susceptibility alleles.
Although the statistical power to test any single rare var-
iant is low [60], direct functional testing and functional an-
notation of variant sites might reveal alleles with modesteffects on ASD susceptibility. Based on the substantial
male bias in autism prevalence and the fact that two of
the suspected neuroligin pathway genes are on the X-
chromosome, we performed comprehensive sequencing of
the NLGN3 (Xp13.1) and NLGN4X (Xp22.3) loci, inclu-
ding the coding exons, 5’UTR, 3’UTR, and flanking in-
tronic and intergenic sequences in 144 male individuals
with ASD obtained from the Autism Genetic Resource
Exchange (AGRE) repository. Our motivation for this de-
sign arises from the fact that male individuals are hemizy-
gous for the X-chromosome, while female individuals are
heterozygous. Thus, recessive acting alleles would be
expressed exclusively in male individuals and could there-
fore increase the prevalence of male ASD. The results of
analysis of our sequence data identified a set of rare non-
coding alleles at highly evolutionarily conserved sites that
were worthy of further evaluation for their role in ASD
susceptibility.
Methods
Selection of male individuals with ASD
We sequenced 144 male individuals from the AGRE
multiplex collection [61]. Detailed diagnostic criteria can
be found on the AGRE website [62]. Male individuals
were chosen from families with two or more male
affected sibpairs (ASPs) that either shared identical X-
chromosome markers, DXS9895 and DXS9902, or shared
> 98% of 52 genotyped single nucleotide polymorphisms
(SNPs) in the Xp22.3 region. A total of 152 families fit
these criteria. One individual was randomly chosen for
sequencing if both affected siblings were equally affected;
if they were not equally affected, those with autism, those
classified as not quite autism (NQA), or those classified as
broad-spectrum were chosen, in that order, to maintain
consistency. Among the 152 samples, two were unavail-
able from the AGRE repository at the time of this ex-
periment and six had global PCR failure. Thus we
had a total of 144 samples for processing. All human
samples used in our study were de-identified and
obtained from the AGRE repository, which obtains
consent to participate in research studies and publish
findings. Our study was reviewed and approved by
the Emory University Institutional Review Board (IRB) be-
cause it met the criteria for exemption under 45 CFR
46.101(b).
Target DNA amplification for the NLGN3 and NLGN4X loci
Long-range PCR (LPCR) primers for amplifying the target
DNA sequence were designed using EmPrime [63]. All pri-
mers were obtained from Invitrogen (Carlsbad, CA, USA)
list of all primers used in this experiment can be found in
Additional file 1. 500 ng of sample DNA was added to 1X
LA Taq buffer (TaKaRa Bio Inc., Otsu Shigh, JP), 250 μM
dNTP Mix (TaKaRa Bio Inc., Otsu Shigh, JP), 400 nM of
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LA Taq (TaKaRa Bio Inc., Otsu Shigh, JP). If the amplicon
had a high GC content, we used 1X GC Buffer (TaKaRa
Bio Inc., Otsu Shigh, JP) in place of 1X LA Taq buffer. PCR
was performed using the following parameters: initial de-
naturation at 94°C for 2 minutes, 29 cycles of 94°C for 10
seconds, 68°C for 1 minute per kilobase (of amplicon size),
and a final extension time of 5 minutes.
Amplification was confirmed using 1% agarose 96-well
E-Gels (Invitrogen, Carlsbad, CA, USA). We determined
the concentration of each amplicon using PicoGreen
dsDNA Quantitation Kits (Invitrogen, Carlsbad, CA, USA)
and the Tecan Ultra Evolution plate reader. An equi-
molar concentration of each fragment was then pooled by
sample for a total DNA concentration per sample of
10 ug. Pooled amplicons were then purified using the
Invitrogen PureLink PCR Purification Kit with the HC
buffer.
Sample preparation for Illumina sequencing
Pooled, purified samples were sheared to approximately
300 bp using the Covaris E210, and fragmentation was
confirmed by running Agilent Bioanalyzer DNA 7500
chips (Agilent Technologies, Santa Clara, CA, USA). We
performed end repair using the NEBNext DNA Sample
Prep Reagent Set 1 (New England BioLabs, Ipswich,
MA, USA) with 0.4 mM dNTP mix, 5 ul of T4 DNA
Polymerase, 1 ul of DNA Polymerase I (Klenow) frag-
ment, 5 ul of T4 Polynucleotide Kinase, and 1X T4
DNA ligase buffer. The reactions were incubated in a
thermal cycler for 30 minutes at 20°C. Following incuba-
tion, the reactions were purified using a QIAquick PCR
Purification Kit (Qiagen, Valencia, CA, USA). To the
purified, blunt, phosphorylated DNA fragments, we
added 1X NEB Buffer 2, 1 mM dATP (NEB, Ipswich,
MA, USA), and 3 ul of Klenow fragment (NEBNext Set
1). Following a 30-minute incubation at 37°C, reactions
were purified using a QIAquick MinElute Kit (Qiagen,
Valencia, CA, USA). To the DNA we added 1X Quick
Ligation Buffer (NEBNext Set 1), 10 ul of Index PE
Adapter Oligo Mix (from the Multiplexing Sample Prep-
aration Kit; Illumina), and 5 ul of Quick T4 DNA Ligase.
The reactions were incubated for 15 minutes at room
temperature, and then purified using the QIAquick PCR
Purification Kit (Qiagen, Valencia, CA, USA). This
protocol uses a 10:1 molar Adapter:DNA ratio based on
the starting concentration of DNA. We used the Size
Select 2% E-Gels (Invitrogen, Carlsbad, CA, USA) to
remove all unligated adapters and to accurately select
the 300-bp band. The 300-bp band was successfully
removed, and then selectively enriched using PCR to
amplify the amount of DNA in the library and attach the
6-base index tag into the adapter. To 10 ul of DNA we
added 1X Phusion PCR Master Mix (Finnzymes, ThermoScientific, Lafayette, Co, USA; NEBNext Set 1), 1 ul
each of PCR Primer lnPE 1.0 and PCR Primer lnPE
2.0, and 1 ul of PCR Primer Index (from Mulitplexing
Sample Preparation Kit; Illumina). PCR parameters
were as follows for 30 cycles: 98°C for 30 seconds,
98°C for 10 seconds, 65°C for 30 seconds, and 72°C
for 30 seconds, with a final extension time of 5 minutes at
72°C. Following incubation, samples were purified using a
QIAquick PCR Purification Kit (Qiagen, Valencia, CA,
USA), and enrichment was confirmed using the Agilent
BioAnalyzer 7500 DNA chip. Four pM of enriched DNA
was used for cluster generation and paired-end sequen-
cing on the Illumina Genome Analyzer II (IGA)
Analysis of Illumina sequence data
Raw base-calling data generated by IGA were used as in-
put for mapping and alignment. Paired-end reads were
mapped and variants were called relative to a reference
sequence using PEMapper (Cutler DJ et al., in revision).
Briefly, the PEMapper is composed of four intercon-
nected programs. The first program prepared a hashed
index of the target sequence, the second program gene-
rated a list of potential mapping locations for each read.
In the third stage, a Smith-Waterman alignment was
performed at each potential location to determine the
optimal position and alignment score. The output of the
third stage, consisting of the pileup statistics of each base
(number of reads where each nucleotide (A, C, G, T) was
seen, together with the number of times that each base
appeared deleted or an insertion immediately following
the base) was used to make the genotype calls.
In total, 99.7% of target bases had at least 8X coverage,
with a median depth of coverage of 452. SNVs and small
insertions and deletions (indels) were annotated using
the Sequence Annotator (SeqAnt) [64]. Functional anno-
tation from hg18 included the genomic position, amino
acid change, presence or absence in dbSNP132, and con-
servation scores (PhastCons, PhyloP) for each variant
base. Additional filtering using dbSNP135 was carried
out using the Feb. 2009, GRCh37(hg19) assembly from
the UCSC Genome Browser [65]. The SNVs at highly
conserved sites had coverages of 198 to 1,354, with the
user base (non-reference allele) being called in > 92% in
the sequence reads at the corresponding variant sites. A
list of all SNVs and indels are contained in Additional
files 2 and 3, respectively. As a comparison, we down-
loaded 3’UTR variants in NLGN3 and NLGN4X from
1,094 individuals sequenced and deposited into the 1000
Genomes database [66]. A total of 49 3’UTR variants (38
SNVs, 11 indels) were identified in the NLGN3 and
NLGN4X genes (see Additional file 4).
We used popgen_fasta2.0.c code to perform population
genetic analyses. This code calculated Watterson’s estima-
tor of the population mutation rate (Θw per site) as well
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[67]. Variants at highly conserved sites were validated in-
dependently by Sanger sequencing (Agencourt Bioscience,
MA). PCR primers for validation were designed using the
Primer 3 [68]. Additionally, we sequenced the mothers
and affected and unaffected male siblings with the vali-
dated UTR variants to verify the segregation pattern with
autism (see Additional file 5). We also sequenced the
mothers and two affected male siblings for two rare novel
intronic variants that fell within transcription factor bind-
ing sites to verify the segregation pattern with autism (see
Additional file 6).
Control genotyping
Control samples used for genotyping were from male
adults of European descent who had been screened to
rule out psychiatric disorders, and were obtained from
the National Institute of Mental Health (NIMH) Human
Genetics Initiative [69]. Genotyping was performed by
the iPLEX Gold Method (Sequenom, San Diego, CA,
USA) per the manufacturer’s instructions, using primers
designed with the Sequenom Assay design 3.1 software
(see Additional file 7). A positive control was included
in each plate to confirm the sensitivity of the assay.
Functional testing of 3’UTR variants in a luciferase assay
Luciferase assays were performed to check whether the
novel UTR variants we identified had altered gene ex-
pression relative to a construct containing the reference
sequence. Full-length UTR sequences were amplified for
three rare variants in NLGN3 (70306922 (C > T),
70306764 (A > G), and 70306767 (C > G), and two rare
variants in NLGN4X (5818136 (A > G), 5820149/50 (CT
> −−)). The amplified sequences were cloned in to the
multiple cloning site, downstream of the luciferase (luc2
+) gene in the pmirGLO expression vector (Promega,
Madison, WI, USA). A full-length 3’UTR sequence am-
plified from an unaffected normal control sample was
cloned in to the same vector as the wild type. The NLGN3
variant (70306764/67) served as the control for non-
conserved UTR variant. The presence of the novel variant
site was confirmed by Sanger sequencing.
Cell culture, transfection, and luciferase assays were
performed on two different cell lines, mouse Neuro2a
and human embryonic kidney 293 (HEK293), following
the manufacturer’s instructions as reported previously
with minor modifications described below [70]. In short,
HEK293 cells and Neuro2a cells were cultured at 37°C
with 5% CO2 in DMEM and RPMI 1640 (Cellgro
Mediatech, Manassas, VA, USA) respectively, supple-
mented with 10% fetal bovine serum (Cellgro Mediatech,
Manassas, VA, USA). Twenty-four hours before transfec-
tion, 0.2*106 cells were plated in each well of 48-well
cell culture dishes. Transfections were carried out usingLipofectamine™ 2000 in Opti-MEM (Invitrogen, Carlsbad,
CA, USA) using 500 ng of plasmid. Just before each trans-
fection, the old media were replaced with fresh media
(DMEM or RPMI supplemented with 10% FBS). Twenty-
four hours post transfection, cells were lysed with 250 ul
of Passive Lysis Buffer (Promega, Madison, WI, USA), and
cell debris were removed by centrifugation at 14,000 rpm
for 5 minutes at 4°C. From each lysate, 20 μl of the cell ex-
tract were transferred into a luminometer tube, and 100 μl
of Dual Luciferase Reporter Assay reagent (Promega,
Madison, WI, USA) was added in each well. A manual
luminometer (TD-20/20, Promega, Madison, WI, USA)
was used to measure the luminescence over a 10-second
period, with a delay time of 2 seconds. The luminometer
reading was repeated after adding 100 ul of Stop and Glo
reagent. For each lysate, the firefly luciferase activity was
normalized to Renilla luciferase activity. We performed
one independent transfection for each of the three 3’UTR
alleles in two different cell lines (mouse Neuro2a and
HEK293). Each transfection was replicated three times. A
two-tailed, unequal variance Student’s t-test was performed
to determine whether constructs with 3’UTR variants
showed altered gene expression compared to constructs
with the reference sequence.
Functional annotation of intronic variants
Annotation of the variants was based on hg build 18 of
the UCSC Genome Browser. Information regarding
the Enhancer- and Promoter-Associated Histone Mark
(H3K4me1 and H3K4me3) and the Transcription Factor
Binding ChIP Seq were obtained from ENCODE Integrated
Regulation tracks. Nuclease accessible site (NAS) informa-
tion was obtained from the EIO/JCVI NAS Track, which
annotates the location of NAS in the genome of human
CD34+ and CD34- cells by NA-Seq technology. Con-
served transcription factor binding sites (TFBS) were from
human/mouse/rat (HMR) conserved TFBS track and were
identified by searching within human-mouse-rat align-
ments using the position weight matrices (PWMs) from
the TRANSFAC Matrix database (v7.0) [71]. The final z
score can be interpreted as the number of standard devia-
tions above the mean raw score for that binding matrix
across the upstream regions of all RefSeq genes. The
conserved transcription factor binding motif was displayed
as a sequence logo [72] obtained at the Sequence Logo
website [73].
Results
We sequenced the NLGN3 and NLGN4X loci in a sam-
ple of 144 male individuals with a diagnosis of autism;
all the patient samples were obtained from the multiplex
AGRE repository. We identified a total of 208 sites of
variation, with 176 SNVs (see Additional file 2), and 32
indels (see Additional file 3). Overall levels of variation
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excess of rare variants as evidenced by a negative value
for the Tajima’s D test statistic (−0.27) [75]. For the
SNVs, a total of 37 (21%), had not been reported before
(18 in NLGN3 and 19 in NLGN4X). For the indels, a
total of 22 (69%), had not been reported before (5 in
NLGN3 and 17 in NLGN4X). As summarized in Figure 1,
almost all common variation (> 5% frequency in our
sample) is contained in dbSNP, whereas most rare var-
iants (< 5%) have not been cataloged in dbSNP.
Our study focused on previously undiscovered var-
iation found at sites with elevated evolutionary conserva-
tion, so we did not follow up the 139 variants included in
dbSNP. The only missense mutation we saw (NLGN4X,
5821532 G > A) had been reported before and, because of
a nearby compensatory mutation, was not predicted to
alter the primary structure of the protein [76]. Our data
provide further evidence that coding sequence mutations
at NLGN3 or NLGN4X that cause autism are very rare.
Assuming the number of disease-causing coding muta-
tions is Poisson distributed, we are 99% confident that the
combined frequency of disease causing coding mutations
at NLGN3 and NLGN4X is less than 3% (no observations
in 144 tries). Functional annotation of the remaining var-
iant sites revealed that six SNVs and one indel were
located at sites with elevated evolutionary conservation
(PhastCons > 0.7, Table 1).
All of the rare variants were observed at a frequency
of less than 1% in our ASD cases. To arrive at a better
estimate of their population frequency, we genotyped six
of the variants in a collection of 1,450 unaffected maleSNV, in dbSNP























Figure 1 Summary of single nucleotide variants (SNV) and insertions
NLGN4X loci in male individuals with autism spectrum disorder (ASD)
against their level of evolutionary conservation. Most common variation ha
and diamonds). Most of the rare variation at both loci was discovered in ou
diamonds).controls obtained from the NIMH Human Genetics Ini-
tiative (Table 1). All of the variants genotyped had a fre-
quency of less than 0.002. Thus, these data suggest that
the variants we found are very rare in the general
population.
Functional analysis of 3’ UTR variants
Rare noncoding variants could act as autism susceptibi-
lity alleles by altering the level of expression of either
NLGN3 or NLGN4X. We sought to determine whether
any of the three highly conserved 3’UTR variants of
NLGN3 (chrX:70306922) and NLGN4X (chrX:5818136,
5820149–50) could potentially lead to altered neuroligin
expression in a luciferase reporter gene assay (Table 1).
In addition to a construct containing the reference se-
quence, we also checked the expression of a construct
containing two rare 3’ UTR NLGN3 variants from a sin-
gle individual (chrX:70306764/67) that were not located
at evolutionary conserved sites, as an internal control.
Each construct was tested in both mouse Neuro2a and
human embryonic kidney 293 (HEK293) cells. The con-
struct bearing the 3’UTR NLGN3 variant (chrX:70306922)
showed a trend for reduced luciferase activity the Neuro2a
(P < 0.10) cells compared to the construct with the refe-
rence sequence (see Additional file 8). However, this result
was not statistically significant and the average reduction
(approximately 9%) was modest. Furthermore, the control
construct showed a similar trend in the Neuro2a cells
(P < 0.22). Neither construct showed a significant differ-
ence in the HEK293 cells (see Additional file 8). Inherit-
ance of the 3’UTR NLGN3 variants did not segregate withINDEL, in dbSNP
INDEL, not in dbSNP
le Frequency
00.050.100.150.20.25
or deletions (indel) variation discovered at the NLGN3 and
. The frequency of SNVs and indels (minor alleles) in cases is plotted
s already been discovered and exists in public databases (blue; circles
r study and not contained in public databases (red; circles and
Table 1 Summary of variants found at sites of increased evolutionary conservation
Functional class Position (hg18) Variant type PhastCons PhyloP Frequency in ASD cases Frequency in NIMH control samples
3’UTR 5818136 SNV 1 2.19 1/144 0/1440
3’UTR 5820149-50 Indel 1 0.85/1.76 1/144 ND
Intron 70284973 SNV 1 1.99 1/144 1/1416
Intron 70285256 SNV 0.98 0.90 1/144 0/1441
Intron 70288838 SNV 0.69 1.03 1/144 2/1441
Intron 70291656 SNV 1 2.52 1/144 0/1440
3’UTR 70306922 SNV 0.73 −0.47 1/144 0/1440
ASD, autism spectrum disorder; NIMH, National Institute of Mental Health; ND, Not Determined.
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novo events in the ASD cases.
The 3’UTR NLGN4X variants did segregate with autism
as shown in Additional file 5. None arose as de novo
events in the ASD cases. A construct with the 3’UTR
NLGN4X SNV (chrX:5818136) suggested a modest trend
for increased luciferase activity in both the Neuro2a
(P < 0.27) and HEK293 (P< 0.23) cells. However, the
difference in expression was not statistically significant in
either case (Additional file 8). The construct with the
3’UTR NLGN4X INDEL was not significant in either cell
type (Additional file 8).
Analysis of intronic variants
We next sought to determine whether any of the four
rare, intronic variants in NLGN3 could act as autism sus-
ceptibility alleles. If so, we would predict that these var-
iants should fall in regions identified as functional by the
ENCODE Project [77]. All of the intronic variants are
located within regions of enriched H3K4Me1 markers in
H1 ES, HMEC, and K562 cells (Figure 2A). Regions with
the mono-methylation of histone H3 lysine 4 are suggest-
ive of enhancer and/or promotor activity due to the epi-
genetic modification of histone proteins [78].
One of the variants (chrX:70291656) was found to be
located within the NAS of CD34- cells, and there are no
common intronic variants located nearby. NAS are loci
that are free of nucleosomes and are therefore hypothe-
sized to allow cis-acting DNA to interact with trans-acting
factors [79]. The same variant (chrX:70291656) also falls
within a HMR conserved Bach1 TFBS (z-score 2.68, P <
0.004) (Figure 2B). Bach1 is a member of the BTB-basic
leucine zipper transcription factor family and is a mam-
malian repressor of heme oxygenase 1 (HO-1) [80]. The
intronic NLGN3 variant chrX:70291656 found at the most
highly evolutionary conserved site did segregate with
autism as shown in Additional file 6.
An additional variant (chrX:70284973) falls within an
HMR conserved Roaz TFBS (z-score 2.86, P< 0.003;
Figure 2C). Roaz is a zinc finger protein that impairs the
ability of the Olf-1/EBF transcription factor family to
activate olfactory neuron-specific promotors [81]. Thisvariant was found in one case and one control. There are
no SNPs or repetitive elements in either of the regions of
TFBS; the closest SNP annotated in dbSNP135 is located
>150 bp upstream or downstream, and repetitive elements
are >1 kbp from either variant. The intronic NLGN3 var-
iant chrX:70284973 also segregates with autism as shown
in Additional file 6.
Discussion
For the past 15 years, genomic studies of complex di-
seases have relied on a model in which common genetic
variation contributes significantly to common diseases
[82-84]. Based on this model, the systematic genotyping
of common variants was perceived as the best way to
begin characterizing the allelic architecture of complex
human traits [85]. To make such experiments possible
required the development of highly accurate, low-cost,
high-throughput genotyping platforms and a catalog of
common human genetic variation like the HapMap pro-
ject [86,87]. Furthermore, because direct sequencing was
not a viable strategy, assessing the role of common var-
iation was really the only feasible genome-wide experi-
ment. Thus, until recently the contribution of rare coding
and noncoding variation to complex disorders like autism
has gone largely unexplored.
While most quantitative traits, including human di-
seases, show substantial heritability in most populations,
their allelic architecture remains poorly understood
[88,89]. Haldane in the 1920s was the first to recognize
that deleterious alleles of large effect will be maintained
only at very low frequencies in the general population
[90]. Copy number variation studies of ASD have identi-
fied variants with a large effect size, having odds ratios
(ORs) often greater than 5.0 [23-34]. Much as Haldane
would have predicted, these variants are quite rare, often
occurring much less often than one in a thousand in the
general population, a frequency generally consistent with
a large effect locus at mutation selection balance.
At the same time, genome-wide association studies
have shown that common variants with large effects are
unlikely to exist in the human population for many dis-




















70291646 70291647 70291648 70291649 70291650 70291651 70291652 70291653 70291654 70291655 70291656 70291657 70291658 70291659 70291660 70291661 70291662
C C CC A T G A G T C C T G C C C
Human C C CC A T G A G T C C T G C C C
Rhesus C C T C A T G A G T C C T G C C C
Mouse C C CC A C G A G T C C T G C C C
Dog C C CC A T G A G T C C T G C C C
Opossum C C T T A T A A G T C C T G C C C
Chicken T G C C A T G G C T T T G G G C T






70284963 70284964 70284965 70284966 70284967 70284968 70284969 70284970 70284971 70284972 70284973 70284974 70284975 70284976 70284977 70284978 70284979
A G C T C CC A T G T G T G A G T
Human A G C T C CC A T G T G T G A G T
Rhesus A G C T C CC A T G T G T G A G T
Mouse A G C T C CC A T G T G T G A G T
Dog A G C T C CC G T G T G T G A G T
Opossum A G C T C CC T T G T G T G A G T
Chicken N N N N N N N N N N N N N N N N N




Figure 2 Genomic location and evolutionary conservation of noncoding variants. (A) The genomic position of highly conserved noncoding
single nucleotide variants (SNVs) in NLGN3 overlap with H3K4Me1 enhancer- and promotor-associated marks in various cell types (orange = H1
embryonic stem cells, green = human mammary epithelial cells (HMEC) and purple = human leukemia cells (K562)); CD34 cells nuclease
accessibility sites (NAS) (purple = sites on CD34+ cells and blue = sites of CD34- cells); and human-mouse-rat (HMR) conserved transcription
factor binding sites (TFBS) (orange blocks). The two variants that fall within HMR TFBS are highlighted in green. (B) Variant (chrX:70291656; also
outlined in a green box) is located within a highly conserved 15-bp Bach1 TFBS (z-score 2.86, P < 0.003;). The sequence logo for the consensus
Bach1 TFBS is shown to the right. The black arrow shows the position of the the variant (chrX:70291656) within this highly conserved binding
motif. (C) Variant (chrX:70284973; outlined in a green box) is located within a highly conserved 14-bp Roaz TFBS (z-score 2.86, P < 0.003). The
sequence logo for the consensus Roaz TFBS is shown to the right. The black arrow shows the position of the the variant (chrX:70284973) within
this highly conserved binding motif.
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[91]). This is borne out in ASD, as genome-wide association
studies have identified just a few loci of interest, which have
largely failed to replicate findings between studies [7,20,21],
whereas a meta-analysis suggests it is extremely unlikely
that any common variant influences autism susceptibility
with an OR of greater than 1.5 [15,22].
Here we used targeted, massively parallel sequencing
of two X-linked genes, previously shown to harbor very
rare point mutations causing ASD, to explore whether
they might also have rare noncoding variants at evolu-
tionary conserved sites that act as ASD susceptibility
alleles. Using this approach we found a set of seven can-
didate variants, including three located in the 3’UTR, in
the two genes examined among the 144 individuals
sequenced (Table 1). As a comparison, a search for simi-
lar variants at highly conserved sites among 1,094 indi-
viduals sequenced and deposited into the 1,000 Genomesdatabase identified a total of 49 3’UTR variants (38 SNVs,
11 indels) identified in NLGN3 and NLGN4X genes
(Additional file 4). None of the indels were found in
highly conserved regions. A total of seven SNVs were
found at highly conserved sites (PhastCons > 0.7), and
two of the variants had an estimated minor allele fre-
quency of 0.001. The remaining five variants did not have
an estimated minor allele frequency. In considering this
comparison, it is important to note that because we
sequenced our samples to a far greater depth as compared
to the 1,000 Genomes samples, our study had a greater
probability of detecting rare variation.
Functional analysis of the 3’ UTR variants in a luciferase
assay did not show a statistically significant difference in
their expression (Additional file 8). The most likely inter-
pretation is that these variants do not influence the risk of
autism in these probands. However, two points are worth
noting. First, under a quantitative genetic model of autism,
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effects (that is, monogenic causes of autism), and instead
might expect to find many alleles at many different loci,
each with modest effects [15,92]. Second, our functional
assays may be imperfect or insufficiently sensitive to reveal
how these variants might act on their respective genes.
Collectively these results point out the challenges of func-
tional validation of alleles with modest effect sizes, even
though the great heterogeneity of autism implies that such
alleles should exist.
Our most promising intronic variant (chrX:70291656)
is located in a highly conserved site in a TFBS that has
been associated with neuronal dysfunction (Figure 2B).
The Bach1 transcription factor protects cells from damage
by activating HO-1. Bach1 dysregulation has been asso-
ciated with Down syndrome (DS): Bach1 is significantly
overexpressed in the fetal cortex of DS fetuses when com-
pared to controls [93], whereas in another study, expres-
sion was significantly reduced in the frontal cortex of DS
patients. In Bach1 knockout mice, expression of Bach1
mRNA was significantly higher in the olfactory bulb, but
lower in the cortex versus wild-type mice, providing an-
other link to olfaction [94]. It is possible the variant we
found within the conserved TFBS influences olfactory
neuron development and expression which could contri-
bute to the sensory dysregulation phenotype of ASD.
Interestingly, the affected individual harboring this variant
in addition to being autistic, is intellectually disabled. He is
diagnosed with sensory abnormalities including increased
sensitivity towards acoustic and decreased sensitivity to-
wards tactile senses. Still, our data do not demonstrate that
this variant is functional through a direct experiment, but
do predict that effects ought to be observed in such an
experiment (for example, ChIP Seq).
Compared to children without neurodevelopmental
disorders, children with ASD demonstrate olfactory and
taste dysfunction [95,96]. Notably, in mice the NLGN3
gene is expressed in all neurons of the olfactory bulb
[40]. It is also interesting that we identified an intronic
variant (chrX:70284973) that falls within a highly con-
served TFBS related to olfactory neuron development
(Figure 2C). Interestingly, this variant is predicted to in-
crease binding efficiency at this TFBS. The Roaz transcrip-
tion factor regulates both the temporal and spatial pattern
of olfactory neuronal gene expression by binding to a con-
sensus recognition sequence and modulating transcrip-
tional activity [81,97]. Over 90% of children with ASD
report sensory abnormalities, among them visual, audi-
tory, tactile, and olfactory dysregulation (reviewed in [98]).
Our results highlight the importance of targeted
sequencing of both coding and noncoding regions of
candidate genes for complex, polygenic traits. Ge-
netic studies of the X-chromosome have suggested
that both rare and common X-linked variation maycontribute to ASD [16,17,31,99-101], but much remains
to be discovered. Although exome sequencing studies are
now identifying point mutations, small indels, and de novo
variants that contribute to ASD [35-37], these studies are
limited by the regions they include in their exome capture
chips, as well as biases in the capture efficiency of paralo-
gous genes. Due to these constraints, these kinds of stu-
dies would have completely missed the noncoding variants
we identified here. A study such as ours is also an impor-
tant follow up for exome studies to assess the complete
spectrum of genetic variation in genes known to harbor
ASD-contributing mutations. These genes are often in
candidate pathways related to neuronal development and
function, and identifying mutations in noncoding and
regulatory regions will likely shed more light on the eti-
ology of ASD pathogenesis. As ASD is a polygenic trait,
noncoding mutations probably play a role in the genetic
contribution to ASD, in combination with other forms of
genetic variation, including CNVs, coding mutations, and
gene-disruptive indels that affect pathways related to brain
development [102]. Still, our study points out that func-
tional testing of rare variants remains challenging and not
sufficiently high-throughput to perform this experiment on
a genome-wide scale, especially when the effect sizes are
modest. Finally, as whole-genome sequencing becomes
increasingly cost effective and a more feasible experi-
mental paradigm, detailed analyses of both coding and
noncoding variation, as we have carried out here, can be
expected to uncover ever more genetic variants that con-
tribute to complex disorders like autism. These studies,
however, will face significant challenges in direct func-
tional testing of large numbers of these rare variants at
highly conserved evolutionary sites.
Conclusions
In conclusion, we used a highly targeted approach to
identify rare variants that may contribute to ASD using
massively parallel sequencing of the X-linked neuronal
cell adhesion genes, NLGN3 and NLGN4X. These data
suggest that coding sequence variations in NLGN3 and
NLGN4X are rare. We identified three 3’UTR SNVs that
did not show statistically significant effects in a lucifer-
ase assay. In addition, we uncovered intronic mutations
that may affect regulatory regions, such as enhancer-
and promotor-associated histone modification sites,
NAS and TFBS. We suspect these variants may make
modest contributions to ASD pathogenesis, as would be
predicted by a quantitative genetic model of autism sus-
ceptibility. These data highlight one of the main chal-
lenges researchers face in the current era of next
generation sequencing technology, namely establishing a
direct link between the candidate variants identified and
its contribution to the clinical phenotype of complex
traits like autism.
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Additional file 1: Table showing long PCR primers. Forward and
reverse primers are listed for each of the regions sequenced.
Additional file 2: Table showing single nucleotide variants detected
in 144 males with diagnosis of autism from the Autism Genetic
Resource Exchange. Contains variant position, dbSNP ID, functional
annotation, and frequency in cases and controls.
Additional file 3: Table showing small insertion and deletion
variants detected in 144 males with diagnosis of autism from the
Autism Genetic Resource Exchange. Contains variant position, dbSNP
ID, functional annotation, and frequency in cases and controls.
Additional file 4: Table showing NLGN3 and NLGN4X 3’UTR genetic
variation from the 1000 Genomes database. Contains variant position,
dbSNP ID, PhastCons score, and estimated frequency.
Additional file 5: Figure showing segregation analysis of the highly
conserved NLGN3 and NLGN4X UTR variants. The segregation of the
highly conserved UTR variants in NLGN3 (chrX:70306922) and NLGN4X
(chrX:5818136, chrX:5820149–50) with a diagnosis of autism were
checked by sequencing the mother and affected and unaffected male
siblings of the corresponding proband. The top base shown is the
reference base, the bottom base shown is the variant base. Both the
NLGN4X variants segregated with autism. We also tested segregation of
the two control variants (chrX:70306764, chrX:70306767) with autism.
DNA was not available for the unaffected sibling of the proband carrying
the NLGN4X UTR variant (chrX:5820149–150).
Additional file 6: Figure showing segregation analysis of two
highly conserved NLGN3 intronic variants. The segregation of NLGN3
intronic variants (chrX:70291656) and (chrX:70284973) with a diagnosis of
autism. Both are located within transcription factor binding sites (TFBS).
Additional file 7: Table showing sequenom genotyping assay
primers for single nucleotide variants discovered in NLGN3 and
NLGN4X loci. This table contains detailed information about each primer
pair and extension primer.
Additional file 8: Figure showing the results of luciferase assays for
one 3’UTR variant in NLGN3 and two 3’UTR variants in NLGN4X. (A).
Results of luciferase expression assay in Neuro2a cell lines. These
constructs were tested against the reference allele constructs using a
luciferase reporter assay. One of the NLGN3 constructs (chrX:70306764/67)
serves as a control for the variant at a non-conserved site. Error bars
show 2 standard errors on either side of the mean value. (B). Results of
luciferase expression assay in human embryonic kidney (HEK) cell lines.
The experiment was similar to that described above.Abbreviations
AGRE: Autism Genetic Resource Exchange; ASD: Autism Spectrum Disorder;
ASP: Affected SibPair; CNV: Copy Number Variant; DMEM: Dulbecco’s
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